Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.00
$0.00
$2K-1.05790 shs1 shs
MannKind Corporation stock logo
MNKD
MannKind
$3.09
-4.0%
$2.74
$2.23
$6.51
$954.66M1.046.59 million shs4.96 million shs
OptiNose, Inc. stock logo
OPTN
OptiNose
$9.60
$9.57
$9.18
$9.75
$97.22M-0.8871,189 shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%+400.00%+400.00%+150.00%-16.67%
MannKind Corporation stock logo
MNKD
MannKind
0.00%-12.22%+12.36%-45.41%-32.39%
OptiNose, Inc. stock logo
OPTN
OptiNose
0.00%0.00%0.00%0.00%+1.91%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.00
$0.00
$2K-1.05790 shs1 shs
MannKind Corporation stock logo
MNKD
MannKind
$3.09
-4.0%
$2.74
$2.23
$6.51
$954.66M1.046.59 million shs4.96 million shs
OptiNose, Inc. stock logo
OPTN
OptiNose
$9.60
$9.57
$9.18
$9.75
$97.22M-0.8871,189 shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%+400.00%+400.00%+150.00%-16.67%
MannKind Corporation stock logo
MNKD
MannKind
0.00%-12.22%+12.36%-45.41%-32.39%
OptiNose, Inc. stock logo
OPTN
OptiNose
0.00%0.00%0.00%0.00%+1.91%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00
N/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
2.60
Moderate Buy$8.84186.21% Upside
OptiNose, Inc. stock logo
OPTN
OptiNose
2.00
Hold$9.00-6.25% Downside

Current Analyst Ratings Breakdown

Latest OPTN, MNKD, and CALA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
MannKind Corporation stock logo
MNKD
MannKind
Boost Price TargetOverweight$8.00 ➝ $10.00
5/7/2026
MannKind Corporation stock logo
MNKD
MannKind
Boost Price TargetBuy$8.00 ➝ $10.00
5/7/2026
MannKind Corporation stock logo
MNKD
MannKind
Boost Price TargetSector Perform$3.50 ➝ $4.75
5/7/2026
MannKind Corporation stock logo
MNKD
MannKind
Lower Price TargetOutperform$8.00 ➝ $7.00
4/28/2026
MannKind Corporation stock logo
MNKD
MannKind
Boost Price TargetOverweight$7.00 ➝ $8.00
4/15/2026
MannKind Corporation stock logo
MNKD
MannKind
UpgradeStrong SellHold
4/13/2026
MannKind Corporation stock logo
MNKD
MannKind
Lower Price TargetOutperform$10.00 ➝ $8.00
3/11/2026
MannKind Corporation stock logo
MNKD
MannKind
DowngradeHoldStrong Sell
3/5/2026
MannKind Corporation stock logo
MNKD
MannKind
Lower Price TargetOutperform$10.00 ➝ $8.00
3/2/2026
MannKind Corporation stock logo
MNKD
MannKind
DowngradeHold (C)Sell (D+)
(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
$360.78M2.65$0.06 per share49.94($0.19) per share-16.26
OptiNose, Inc. stock logo
OPTN
OptiNose
$81.86M1.19N/AN/A($11.56) per share-0.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$39.65MN/AN/AN/AN/AN/AN/AN/A5/18/2026 (Estimated)
MannKind Corporation stock logo
MNKD
MannKind
$5.86M-$0.07N/A20.60N/A-6.63%-11.21%-3.92%8/5/2026 (Estimated)
OptiNose, Inc. stock logo
OPTN
OptiNose
-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%N/A

Latest OPTN, MNKD, and CALA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
MannKind Corporation stock logo
MNKD
MannKind
-$0.02-$0.05-$0.03-$0.05$105.38 million$90.17 million
2/26/2026Q4 2025
MannKind Corporation stock logo
MNKD
MannKind
-$0.01-$0.05-$0.04-$0.05$99.85 million$111.96 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/A
1.87
1.50
OptiNose, Inc. stock logo
OPTN
OptiNose
N/A
0.79
0.72

Institutional Ownership

CompanyInstitutional Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/A
MannKind Corporation stock logo
MNKD
MannKind
49.55%
OptiNose, Inc. stock logo
OPTN
OptiNose
85.60%

Insider Ownership

CompanyInsider Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
6.60%
MannKind Corporation stock logo
MNKD
MannKind
2.60%
OptiNose, Inc. stock logo
OPTN
OptiNose
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
603.86 million4.55 millionNot Optionable
MannKind Corporation stock logo
MNKD
MannKind
400308.95 million300.92 millionOptionable
OptiNose, Inc. stock logo
OPTN
OptiNose
19010.13 million9.83 millionNot Optionable

Recent News About These Companies

Optinose reports Q4 EPS (3c) vs ($1.33) last year
Optinose downgraded to Neutral from Buy at H.C. Wainwright
Optinose downgraded to Neutral from Overweight at Piper Sandler
Optinose downgraded to Hold from Buy at Lake Street
Lake Street Downgrades OptiNose (OPTN)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Calithera Biosciences stock logo

Calithera Biosciences NASDAQ:CALA

$0.0005 0.00 (0.00%)
As of 05/15/2026

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

MannKind stock logo

MannKind NASDAQ:MNKD

$3.09 -0.13 (-4.04%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$3.09 +0.00 (+0.10%)
As of 05/15/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

OptiNose stock logo

OptiNose NASDAQ:OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.